中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

聚乙二醇干扰素α-2a/2b联合利巴韦林复治慢性丙型肝炎患者的疗效观察

朱研 毛青 张长江 孙伟 胡亚君 谭朝霞 王小红

朱研, 毛青, 张长江, 孙伟, 胡亚君, 谭朝霞, 王小红. 聚乙二醇干扰素α-2a/2b联合利巴韦林复治慢性丙型肝炎患者的疗效观察[J]. 临床肝胆病杂志, 2011, 27(1): 86-88.
引用本文: 朱研, 毛青, 张长江, 孙伟, 胡亚君, 谭朝霞, 王小红. 聚乙二醇干扰素α-2a/2b联合利巴韦林复治慢性丙型肝炎患者的疗效观察[J]. 临床肝胆病杂志, 2011, 27(1): 86-88.
Zhu Yan, Mao Qing, Zhang ZhangJiang, Sun Wei, Hu YaJun, Tan ChaoXia, Wang XiaoHong. Retreatment with pegylated interferon alpha-2a/2b and ribavirin in previous relapsers with chronic hepatitis C[J]. J Clin Hepatol, 2011, 27(1): 86-88.
Citation: Zhu Yan, Mao Qing, Zhang ZhangJiang, Sun Wei, Hu YaJun, Tan ChaoXia, Wang XiaoHong. Retreatment with pegylated interferon alpha-2a/2b and ribavirin in previous relapsers with chronic hepatitis C[J]. J Clin Hepatol, 2011, 27(1): 86-88.

聚乙二醇干扰素α-2a/2b联合利巴韦林复治慢性丙型肝炎患者的疗效观察

详细信息
  • 中图分类号: R512.63

Retreatment with pegylated interferon alpha-2a/2b and ribavirin in previous relapsers with chronic hepatitis C

  • 摘要:

    目的探讨聚乙二醇干扰素α(PEG-IFNα)联合利巴韦林治疗复发慢性丙型肝炎(CHC)患者的应答情况及影响因素。方法 30例经IFN-α或PEG-IFNα标准RGT治疗后复发的CHC患者,均用PEG-IFNα-2a(180μg)或PEG-IFNα-2b(1.5μg/kg)联合利巴韦林(900 mg/d)再治疗,基因1型治疗48周,非基因1型治疗24周,停药随访24周,分析病毒基因型、基线HCV RNA载量、初治药物种类对联合治疗疗效的影响。结果 30例复发患者经联合再治疗后,24例(80%)获得持续病毒学应答(SVR)。18例低病毒载量(HCV RNA≤105拷贝/ml)患者中,17例(94.4%)获得SVR,与高病毒载量组(58.3%)差异有统计学意义(P=0.026)。基因1型组18例,其中14例(77.8%)获得SVR,与非基因1型组(83.3%)差异无统计学意义(P=1.000)。初治应用PEG-IFNα联合利巴韦林抗病毒的患者17例,其中13例(76.5%)经再治疗后获得SVR,与初治应用IFN-α抗病毒组(84.6%)无明显差异(P=0.672)。结论 PEG-IFNα联合...

     

  • [1]Sherman M, Shafran S, Burak K, et al.Management of chronic hepatitis C:consensus guidelines[J].Can J Gastroenterol, 2007, 21 (Suppl C) :25C-34C.
    [2]Hadziyannis SJ, Sette H Jr, Morgan TR, et al.Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C:a randomized study of treatment duration and ribavirin dose[J].Ann Intern Med, 2004, 140 (5) :346-355.
    [3]Chinese society of infectious diseases and parasitology and chinese society of hepatology of Chinese medical association.The programme of prevention and cure for viral hepatitis[J].Chin J Hepatol, 2000, 8 (6) :324-329.
    [4]熊瑜琳, 张长江, 王小红, 等.中国人HCV标本库的建立[J].免疫学杂志, 2008, 24 (5) :568-571.
    [5]Sherman M, Yoshida EM, Deschenes M, et al.Peginterferon alfa-2a (40 KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy[J].Gut, 2006, 55 (11) :1631-1638.
    [6]Yoshida EM, Sherman M, Bain VG, et al.Re-treatment with pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy[J].Can J Gastroenterol, 2009, 23 (3) :180-184.
    [7]Poynard T, Colombo M, Bruix J, et al.Peginterferon alfa-2b and ribavirin:effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy[J].Gastroenterology, 2009, 136 (5) :1618-1628.
    [8]Ge D, Fellay J, Thompson AJ, et al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J].Nature, 2009, 461 (7262) :399-401.
    [9]Suppiah V, Moldovan M, Ahlenstiel G, et al.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy[J].Nat Genet, 2009, 41 (10) :1100-1104.
    [10]Tanaka Y, Nishida N, Sugiyama M, et al.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C[J].Nat Genet, 2009, 41 (10) :1105-1109.
    [11]Shiratori Y, Kato N, Yoshida H, et al.How soon can a virological sustained response be determined after withdrawal of interferon therapy in chronic hepatitis C?Tokyo-Chiba Hepatitis Research Group[J].J Gastroenterol Hepatol, 1999, 14 (1) :79-84.
  • 加载中
计量
  • 文章访问数:  2311
  • HTML全文浏览量:  13
  • PDF下载量:  827
  • 被引次数: 0
出版历程
  • 出版日期:  2011-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回